Generic Abilify (Aripiprazole) Approved

On April 28, 2015 the U.S. Food and Drug Administration (FDA) approved the generic formulation (Aripiprazole), of Otsuka America Pharmaceuticals’ brand Abilify®. Aripiprazole is an atypical antipsychotic indicated for the treatment of bipolar depression and schizophrenia. It is also indicated as adjunct therapy in the treatment of depression when antidepressant monotherapy is inadequate. Non-bipolar depression … Read moreGeneric Abilify (Aripiprazole) Approved